Basic phospholipase A2 BmjeTX-I (103-119), pBmje

General Information


DRACP ID  DRACP04261

Peptide Name   Basic phospholipase A2 BmjeTX-I (103-119), pBmje

Sequence  YNKKYRYHLKSCKKADK

Sequence Length  17

UniProt ID  P86803 

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Active ACP



Activity Information


Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer; Antibacterial; Antiparasitic



Structure Information


PDB ID  Not available

Predicted Structure  Not available

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Amidation

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C98H157N29O25S

Absent amino acids  EFGIMPQTVW

Common amino acids  K

Mass  245913

Pl  10.47

Basic residues  8

Acidic residues  1

Hydrophobic residues  2

Net charge  7

Boman Index  -6405

Hydrophobicity  -204.12

Aliphatic Index  28.82

Half Life 
  Mammalian: 2.8 hour
  Yeast: 10 min
  E.coli: 2 min

Extinction Coefficient cystines  4470

Absorbance 280nm  279.38

Polar residues  6

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 34130109

Title  Dissection of phospholipases A 2 reveals multifaceted peptides targeting cancer cells, Leishmania and bacteria

Doi Not available

Year  2021

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DBAASP ID  18753

DRACP is developed by Dr.Zheng's team.